Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Osteoporos Int ; 30(4): 787-795, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30796539

ABSTRACT

Whether early chronic kidney disease (CKD) is associated with fracture in middle-aged adults is unclear. In a cross-sectional analysis of the CARTaGENE survey, we observed that early CKD was not associated with increased fracture, did not modify the association between calcaneal QUS and fracture, but modified the association between clinical, pharmacological parameters and fracture. INTRODUCTION: The association between advanced CKD and increased fracture risk is well described. However, whether early CKD is associated with increased fractures, especially in middle-aged adults, is unclear. We aimed to assess if early CKD is associated with increased fracture status and whether early CKD status modifies the association between calcaneal quantitative ultrasound parameters, clinical, pharmacological parameters, and fractures. METHODS: Cross-sectional analysis of CARTaGENE, a population-based survey of 40- to 69-year-old individuals. Individuals with CKD (stage 2, estimated glomerular filtration rate [eGFR] 60-89 ml/min/1.73 m2; stage 3, eGFR 30-59) were compared to non-CKD individuals (eGFR > 90). Fracture status (excluding face, toe, hand, and patella) was identified through a questionnaire at baseline. Calcaneal quantitative ultrasound (QUS) was measured in each participant. RESULTS: A total of 17,608 individuals (656 CKD stage 3; 8227 stage 2; 8725 non-CKD) were included. CKD stage 2 and 3 individuals (mean eGFR 78 and 53 ml/min/1.73 m2) were older and had more diabetes, cardiovascular disease, and hypertension. Fracture status prevalence was 14.9% in CKD stage 3, 10.8% in CKD stage 2, and 9.0% in non-CKD individuals. Fracture status prevalence was similar between CKD and non-CKD individuals when stratified by age or after adjustment for demographic and clinical parameters. QUS stiffness index was associated with fracture status in both CKD stage 3 (standardized odds ratio [sOR] = 1.525 [1.200 to 1.939] per 1 SD decrease), stage 2 (sOR = 1.415 [1.310 to 1.530]), and non-CKD individuals (sOR = 1.477 [1.361 to 1.602]). The associations between blood pressure, antihypertensive, and fracture status followed a U-shape throughout the progression of CKD. CONCLUSIONS: CKD stage 3 was not associated with an increase in fracture status. QUS parameters were similarly associated with fracture status in patients with and without CKD.


Subject(s)
Osteoporotic Fractures/etiology , Renal Insufficiency, Chronic/complications , Adult , Age Distribution , Aged , Calcaneus/diagnostic imaging , Cross-Sectional Studies , Female , Glomerular Filtration Rate , Health Surveys , Humans , Male , Middle Aged , Osteoporotic Fractures/diagnostic imaging , Osteoporotic Fractures/epidemiology , Prevalence , Quebec/epidemiology , Renal Insufficiency, Chronic/epidemiology , Renal Insufficiency, Chronic/physiopathology , Severity of Illness Index , Ultrasonography
2.
Am J Transplant ; 13(4): 861-874, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23432943

ABSTRACT

Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. We reported previously that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3. Here, we tested the possibility that LG3 behaves as a neoantigen, fuelling the production of anti-LG3 antibodies of potential importance in regulating allograft vascular injury. We performed a case-control study in which we compared anti-LG3 IgG titers in kidney transplant recipients with AVR (n=15) versus those with acute tubulo-interstitial rejection (ATIR) (n=15) or stable graft function (n=30). Patients who experienced AVR had elevated anti-LG3 titers pre and posttransplantation compared to subjects with ATIR or stable graft function (p<0.05 for both mediators). Elevated pretransplant anti-LG3 titers (OR: 4.62, 95% CI: 1.08-19.72) and pretransplant donor-specific antibodies (DSA) (OR 4.79, 95% CI: 1.03-22.19) were both independently associated with AVR. To address the functional role of anti-LG3 antibodies in AVR, we turned to passive transfer of anti-LG3 antibodies in an animal model of vascular rejection based on orthotopic aortic transplantation between fully MHC-mismatched mice. Neointima formation, C4d deposition and allograft inflammation were significantly increased in recipients of an ischemic aortic allograft passively transferred with anti-LG3 antibodies. Collectively, these data identify anti-LG3 antibodies as novel accelerators of immune-mediated vascular injury and obliterative remodeling.


Subject(s)
Graft Rejection/immunology , Heparan Sulfate Proteoglycans/immunology , Immunoglobulin G/blood , Vascular Diseases/immunology , Adult , Animals , Antigens/immunology , Aorta/pathology , Apoptosis , Case-Control Studies , Endothelial Cells/pathology , Female , Graft Rejection/blood , Humans , Immunization, Passive , Immunoglobulin G/immunology , Inflammation/pathology , Kidney/blood supply , Kidney/pathology , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Middle Aged , Recombinant Proteins/immunology , Retrospective Studies , Vascular Diseases/blood
3.
Ann Biol Clin (Paris) ; 65(1): 71-6, 2007.
Article in French | MEDLINE | ID: mdl-17264042

ABSTRACT

The management of metabolic problems following parathyroidectomy in end stage renal disease remains poorly defined. Hypocalcemia is a common and serious complication in the post-operative period. The objective of the present study was to develop a protocol for the management of patients during the immediate perioperative period based on the best available data from the literature, and to verify its effectiveness and safety in three patients on chronic hemodialysis. A patient management protocol was developed based on data reported in the literature and was subsequently tested on three chronic dialysis patients suffering from tertiary hyperparathyroidism with an indication of parathyroidectomy. According to the literature, the risk of hypocalcemia following parathyroidectomy can be decreased by tight surveillance of calcium levels and preventive administration of calcium and vitamin D analogue to patients at high risk of hypocalcemia. By applying this protocol, profound hypocalcemia was avoided and the immediate post-operative period was uneventful in the three patients under study. In summary, the proposed protocol is safe and effective for the peri-parathyroidectomy management of patients on chronic hemodialysis.


Subject(s)
Hyperparathyroidism, Secondary/surgery , Hypocalcemia/prevention & control , Kidney Failure, Chronic/complications , Parathyroidectomy , Perioperative Care , Phosphorus/blood , Adult , Bone Density Conservation Agents/therapeutic use , Calcium/blood , Calcium, Dietary/therapeutic use , Clinical Protocols , Female , Humans , Hyperparathyroidism, Secondary/etiology , Male , Middle Aged , Vitamin D/therapeutic use
7.
Am J Kidney Dis ; 38(6): 1271-6, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11728960

ABSTRACT

Coronary artery disease (CAD) is the leading cause of death in patients with end-stage renal disease (ESRD). Recent evidence suggests that the expression of Fas, a molecule implicated in the initiation of apoptosis in various cell types, is increased at sites of atherosclerotic plaques. However, the significance of plasma levels of the soluble form of Fas (sFas) and its ligand (sFas-L) as markers of atherosclerosis has yet to be defined. The present report is a cross-sectional analysis of baseline data from an ongoing prospective study designed to evaluate the role of sFas and sFas-L as markers of CAD in ESRD. We evaluated the association between plasma levels of sFas and sFas-L and evidence of CAD in a cohort of 107 chronic hemodialysis patients. Plasma levels of sFas were significantly greater (P = 0.04) among subjects with (n = 64) than without evidence of CAD (n = 43). Plasma levels of sFas-L were similar in both groups. Using multivariate analysis, sFas level was found to be independently associated with CAD (P = 0.01) after adjustment for classic risk factors for CAD (hyperlipidemia, diabetes, hypertension, and smoking), markers of inflammation (C-reactive protein [CRP], intercellular adhesion molecule 1), and other confounders. An increase of one quintile in plasma concentration of sFas was associated with an odds ratio for CAD of 1.64 (95% confidence interval, 1.11 to 2.41). Models that incorporated sFas were significantly better at identifying patients with CAD than models limited to classic risk factors for atherosclerosis, alone (P = 0.008) or in combination with CRP levels (P = 0.006). In summary, increased plasma levels of sFas are associated with CAD in stable patients with ESRD. These results suggest that sFas may represent a novel and independent marker of CAD.


Subject(s)
Coronary Disease/complications , Coronary Disease/diagnosis , Kidney Failure, Chronic/complications , fas Receptor/blood , Aged , Apoptosis , Biomarkers/blood , C-Reactive Protein/analysis , Confidence Intervals , Coronary Disease/blood , Female , Humans , Intercellular Adhesion Molecule-1/blood , Interleukin-2/blood , Logistic Models , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Prospective Studies , Risk Factors , Vascular Cell Adhesion Molecule-1/blood
9.
Can J Cardiol ; 16(2): 153-61, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10694585

ABSTRACT

OBJECTIVE: To determine whether the success and complication rates of oral anticoagulation obtained in large, well controlled trials, upon which recommendations are based, are comparable with routine cardiology practice. DESIGN: An observational, prospective cohort study collected data on all patients followed at an anticoagulant clinic over one calendar year. PATIENTS: One thousand and seventy-eight patients anticoagulated for cardiovascular indications, mainly atrial fibrillation, prosthetic valves and ventricular dysfunction, were followed for 804 patient-years of treatment. No patient was lost to follow-up. INTERVENTIONS: Telephone conversations and regular verification of medical files were used to record and classify all bleeding and thromboembolic events according to severity. International normalized ratios (INR) were compared with target ranges. RESULTS: One hundred and twelve bleeding events, ie, 13.9/100 patient-years (% p-y), were recorded, of which 61 required medical attention. Major hemorrhages, defined as those requiring treatment or hospital observation for more than 24 h, occurred in 15 instances (1.9% p-y). Among these, 9 (1.1% p-y) were classified as life threatening, with four being fatal (0,5% p-y). Twenty-two thromboembolic events (2.7% p-y) occurred, of which 10 were major (1.2% p-y), leaving three patients (0.4% p-y) with long term sequelae and causing two deaths (0.25% p-y). INRs were within target range 62.3% of the time, with 2.2% of values recorded above 5 and 0.3% above 10. CONCLUSION: The low failure and complication rates obtained in large, controlled trials are similar to those observed in actual cardiology practice.


Subject(s)
Anticoagulants/administration & dosage , Heart Diseases/drug therapy , Thromboembolism/drug therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Atrial Fibrillation/drug therapy , Cohort Studies , Female , Follow-Up Studies , Heart Valve Prosthesis Implantation , Hemorrhage/chemically induced , Hospitals, University , Humans , International Normalized Ratio , Male , Middle Aged , Postoperative Complications/drug therapy , Prospective Studies , Quebec , Ventricular Dysfunction, Left/drug therapy
10.
Nephrol Dial Transplant ; 15(2): 231-4, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10648670

ABSTRACT

BACKGROUND: Partial replantation (i.e. replacement of the extraperitoneal portion of the catheter with creation of a new subcutaneous tunnel) has been suggested to avoid catheter removal in patients with persistent exit-site/tunnel infection (ESTI). However, published experience with this technique is limited. METHODS: Partial replantation was performed on an outpatient basis under local anesthesia for seven patients with persistent ESTI of >3 months duration. All patients resumed CAPD immediately following surgery. RESULTS: One patient had dialysate leakage less than 1 week after surgery that required catheter removal. The other patients had no complications and mean catheter survival following surgery was 7. 7 months (range 3.5-13 months). There was no recurrence of ESTI after surgery, although two patients presented with exit-site infection unrelated to the initial episode (i.e. different organism, long latency). Three other patients presented with episodes of peritonitis unrelated to surgery (i.e. delay >1 month) or ESTI (i.e. different organism). CONCLUSIONS: Partial replantation allows significant prolongation of catheter survival without major complications or interruption of CAPD. This novel procedure appears to be an appropriate alternative to catheter removal for the management of persistent ESTI. However, further studies are needed to prospectively compare partial replantation with catheter removal.


Subject(s)
Ambulatory Care , Catheters, Indwelling , Peritoneal Dialysis, Continuous Ambulatory , Peritoneal Dialysis, Continuous Ambulatory/instrumentation , Aged , Catheters, Indwelling/adverse effects , Equipment Reuse , Humans , Infections/etiology , Medical Illustration , Middle Aged , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Reoperation
11.
Kidney Int ; 57(2): 578-89, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10652035

ABSTRACT

BACKGROUND: The Health Care Financing Administration's End-Stage Renal Disease (ESRD) Core Indicators Project collects clinical information on prevalent adult patients receiving in-center hemodialysis (HD) care in the United States to assess the quality of care delivered. Although hematocrit values, transferrin saturations, and iron prescription practices have improved over the last five years, we sought to determine whether continued opportunities for improvement of this domain of care exist. METHODS: A random sample of 7292 adult in-center HD patients was selected. Dialysis facility staff provided clinical information for the period of October through December 1996 for 6858 (94%) patients; complete laboratory information was available from 4991 (73%) returned forms. Hematocrit values, transferrin saturations, serum ferritin concentrations, epoetin alfa dosing, and iron prescriptions were abstracted from patient medical records to assess anemia management practices. RESULTS: The mean hematocrit for this cohort was 32.6 +/- 3.5%. Seventy-two percent of patients had hematocrit values> 30%. Forty-two percent had hematocrit values of 33 to 36%, and 10% were severely anemic (hematocrit <28%). Ninety-four percent of the patients received epoetin alfa intravenously (i.v.) and 6% subcutaneously. The mean weekly dose was 202.4 +/- 137.2 units/kg. The mean transferrin saturation was 27.4 +/- 12.6%; 73% of patients had a mean transferrin saturation > or = 20%. The mean serum ferritin concentration was 386 +/- 422 ng/mL; 79 and 12% of patients had a serum ferritin concentration of> 100 and> 800 ng/mL, respectively. Nine percent of the sample (N = 434) had a transferrin saturation <20% and serum ferritin concentration <100 ng/mL. Regardless of the patient's transferrin saturation, approximately three fourths of the patients received either oral or i.v. iron, and only approximately one half of the patients received i.v. iron. Of the subset of patients with transferrin saturation <20% and serum ferritin concentration <800 ng/mL, only 53% were prescribed intravenous iron. Multivariate linear regression analysis revealed that serum albumin, urea reduction ratio, age, and transferrin saturation were significantly positively associated with hematocrit. Epoetin alfa dose and serum ferritin concentration were significantly and negatively associated with the hematocrit (P < 0.001). CONCLUSION: Although substantial improvements have been made in anemia management for adult in-center HD patients over the past five years, significant opportunities persist to improve iron prescription practices.


Subject(s)
Anemia/drug therapy , Kidney Failure, Chronic/therapy , Quality Indicators, Health Care , Renal Dialysis/standards , Adult , Aged , Ambulatory Care/standards , Anemia/etiology , Epoetin Alfa , Erythropoietin/administration & dosage , Female , Ferritins/blood , Hematinics/administration & dosage , Hematocrit , Humans , Iron/administration & dosage , Kidney Failure, Chronic/complications , Male , Middle Aged , Multivariate Analysis , Recombinant Proteins , Serum Albumin , Transferrin/analysis , United States
12.
Am J Kidney Dis ; 32(5): 802-7, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9820450

ABSTRACT

Cross-sectional and prospective studies of men suggest a positive association between nephrolithiasis and hypertension. However, this association remains controversial in women. We conducted a prospective study of the relation between nephrolithiasis and the risk for hypertension in the Nurses' Health Study, a cohort of 89,376 women aged 34 to 59 years in 1980. Information on the history of nephrolithiasis, physician-diagnosed hypertension, and other relevant exposures was obtained by biennial mailed questionnaire. A history of nephrolithiasis before 1980 was reported by 2,558 women (2.9%), and a history of hypertension was reported by 11,883 women (13.3%). Among women without hypertension before 1980, 12,540 women reported a new diagnosis of hypertension between 1980 and 1992, during 711,039 person-years of follow-up. Compared with those without a history of nephrolithiasis, the age-adjusted relative risk (RR) for incident hypertension in women with such a history was 1.36 (95% confidence interval [CI], 1.20 to 1.43). After further adjustment for body mass index (BMI) and the intake of calcium, sodium, potassium, magnesium, caffeine, and alcohol, the RR was only slightly attenuated (RR=1.24; 95% CI, 1.13 to 1.37). In contrast, the occurrence of incident nephrolithiasis during follow-up was similar in women with hypertension at baseline compared with women without (adjusted odds ratio [OR]=1.01; 95% CI, 0.85 to 1.20). These data are consistent with the results obtained in men and support the hypothesis that a history of nephrolithiasis is associated with an increased risk for subsequent hypertension. Dietary factors, such as the intake of calcium, sodium, and potassium, do not explain this association. Unidentified pathogenic mechanisms common to nephrolithiasis and hypertension may be responsible for the development of both disorders.


Subject(s)
Hypertension/etiology , Kidney Calculi/complications , Adult , Alcohol Drinking , Body Mass Index , Caffeine/administration & dosage , Calcium, Dietary/administration & dosage , Cohort Studies , Confidence Intervals , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Hypertension/epidemiology , Incidence , Kidney Calculi/epidemiology , Magnesium/administration & dosage , Male , Middle Aged , Odds Ratio , Potassium, Dietary/administration & dosage , Prospective Studies , Risk Factors , Sodium, Dietary/administration & dosage , Surveys and Questionnaires , United States/epidemiology
13.
Am J Hypertens ; 11(1 Pt 1): 46-53, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9504449

ABSTRACT

A positive association between nephrolithiasis and blood pressure has been suggested in previous studies. However, controversy remains, due to methodological problems in some of the previous studies and absence of prospective data. We evaluated the relationship between nephrolithiasis and the risk of hypertension in a cohort of 51,529 men followed prospectively for 8 years. Information was obtained by biennial mailed questionnaires. At baseline in 1986, 4111 (8.0%) subjects reported a history of nephrolithiasis and 11,623 (22.6%) a diagnosis of hypertension. A positive association was found between the two disorders (age adjusted odds ratio [OR]: 1.31; 95% confidence interval [CI]: 1.30 to 1.32). Among men who reported both disorders, 79.5% reported that the occurrence of nephrolithiasis was prior to or concomitant with the diagnosis of hypertension. Among men without hypertension at baseline, the odds ratio for incident hypertension in men with a history of nephrolithiasis compared with those without was 1.29 (95% CI: 1.12 to 1.41; adjusted for age, body mass index, and intake of calcium, sodium, potassium, magnesium, and alcohol). The occurrence of incident nephrolithiasis during follow-up was similar in men with hypertension at baseline compared with that in men without (adjusted OR: 0.99, 95% CI: 0.82 to 1.21). These data support the hypothesis that prior occurrence of nephrolithiasis increases the risk of subsequent hypertension.


Subject(s)
Hypertension/etiology , Kidney Calculi/complications , Adult , Aged , Blood Pressure , Cross-Sectional Studies , Follow-Up Studies , Humans , Hypertension/physiopathology , Kidney Calculi/physiopathology , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Risk Factors
14.
J Am Soc Nephrol ; 8(12): 1921-9, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9402095

ABSTRACT

Despite the prevalent use of recombinant human erythropoietin (rhEPO), anemia is a frequent finding in hemodialysis patients. The goal of this study was to evaluate the impact of anemia on patient survival and characterize the determinants of hematopoiesis that may be amenable to therapeutic manipulation to enhance rhEPO responsiveness and reduce death risk. Patient characteristics and laboratory data were collected for 21,899 patients receiving hemodialysis three times per week in dialysis centers throughout the United States in 1993. Hemoglobin concentrations (Hb) < or =80 g/L were associated with a twofold increase in the odds of death (odds ratio = 2.01; P = 0.001) when compared with Hb 100 to 110 g/L. No improvement in the odds of death was afforded for Hb >110 g/L. Using multiple linear regression, variables of rhEPO administration (rhEPO dose and percentage of treatments that rhEPO was administered), variables of iron status (serum iron, transferrin saturation, and ferritin), variables of nutritional status (serum albumin and creatinine concentration), and the dose of dialysis (urea reduction ratio) were found to be significantly associated with hemoglobin concentration (P < 0.001). Age, race, and gender were also found to be significantly associated with hemoglobin concentrations (P < 0.001). From this report, the following conclusions may be made. (1) Anemia may be predictive of an increased risk of mortality in some hemodialysis patients. (2) Hemoglobin concentrations > 110 g/L are not associated with further improvements in the odds of death. (3) Laboratory surrogates of iron stores, nutritional status, and the delivered dose of dialysis are predictive of hemoglobin concentration. Whether manipulation of the factors that improve anemia will also enhance the survival of patients on hemodialysis is unknown and should be evaluated by prospective, interventional studies.


Subject(s)
Anemia/epidemiology , Kidney Failure, Chronic/complications , Renal Dialysis/adverse effects , Adult , Aged , Anemia/etiology , Anemia/prevention & control , Anemia, Hypochromic/epidemiology , Anemia, Hypochromic/etiology , Comorbidity , Creatinine/blood , Diabetes Mellitus/epidemiology , Erythropoietin/therapeutic use , Female , Ferritins/blood , Hemoglobins/analysis , Humans , Iron/metabolism , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/therapy , Male , Middle Aged , Nutrition Disorders/epidemiology , Odds Ratio , Predictive Value of Tests , Prevalence , Recombinant Proteins/therapeutic use , Regression Analysis , Risk Factors , Serum Albumin/analysis , Survival Analysis , Transferrin/analysis , Treatment Outcome , United States/epidemiology
15.
Am J Kidney Dis ; 30(5): 665-71, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9370182

ABSTRACT

Nitric oxide (NO) is a powerful vasoactive agent that contributes to the regulation of blood pressure (BP). However, the role of NO in uremic patients and during the course of hemodialysis is still debated. Blood L-arginine concentrations and exhaled NO concentrations were measured in 22 healthy controls and in 22 hemodialysis patients before and after dialysis. On the basis of their BP response during hemodialysis, the patients were divided into three groups: 6 of the 22 patients presented with a decrease in BP during dialysis (group 1), eight presented with a stable BP (group 2), and eight with an increase in BP (group 3). The exhaled NO concentration was higher in dialysis patients than in healthy controls (22.7 +/- 2.6 ppb in dialysis patients v 16.7 +/- 0.9 ppb in controls, mean +/- SEM, P = 0.044). The predialysis and postdialysis exhaled NO concentrations were inversely correlated with the change in BP during hemodialysis (r = -0.47, P = 0.013). Patients with a decrease in BP (group 1) had the highest NO concentrations; patients with an increase in BP (group 3) had the lowest values; and patients with a stable BP during the course of dialysis (group 2) had intermediary values (trend test, P = 0.0291). In addition, both the exhaled NO concentration and the blood L-arginine concentration decreased during dialysis in all patients (P = 0.005 and P = 0.001, respectively). These results provide several novel insights into NO metabolism and BP regulation during hemodialysis: (1) maintenance hemodialysis is associated with a chronic increase in NO concentrations; (2) changes in BP during hemodialysis are inversely correlated with exhaled NO concentrations, higher NO levels being associated with a decrease in BP and lower NO levels with an increase in BP during dialysis; (3) blood L-arginine levels decrease during hemodialysis, and this reduction may in turn influence NO production.


Subject(s)
Blood Pressure/physiology , Nitric Oxide/physiology , Renal Dialysis , Adult , Analysis of Variance , Arginine/blood , Breath Tests/methods , Female , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/physiopathology , Kidney Failure, Chronic/therapy , Luminescent Measurements , Male , Middle Aged , Nitric Oxide/analysis
16.
Am J Kidney Dis ; 28(6): 931-6, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8957049

ABSTRACT

Long-term survival with end-stage renal disease (ESRD) on dialysis is uncommon, mainly because of the high mortality associated with cardiovascular disease. To define the clinical characteristics of long-term ESRD survivors, especially their cardiovascular risk profile, patients were identified with > or = 15 years of ESRD having at least 10 years on dialysis. Seventeen patients were identified with a duration of ESRD of 21.0 +/- 4.3 years (mean +/- SD). The age of the patients at the initiation of dialysis was 38.4 +/- 14.5 years. Eighty-eight percent of the survivors were white, and 12% were African-American. The primary causes of ESRD were glomerulonephritis, 65%; polycystic kidney disease, 18%; tubulointerstitial/obstructive disorders, 12%; and hypertension, 6%. At the initiation of dialysis, these long-term survivors presented with a low prevalence of cardiovascular risk factors (hypertension, 53%; diabetes mellitus, 0%; active smoking, 11.8%; family history, 25%) and cardiovascular disease (coronary heart disease, 5.9%; congestive heart failure, 5.9%; arrhythmias, 0%; peripheral vascular disease, 0%; and cerebrovascular disease, 5.9%). In addition, only 6.6% of the long-term ESRD survivors presented with systolic blood pressures < 110 mm Hg, a level suggestive of systolic dysfunction. After > or = 15 years of dialysis, these long-term survivors remained with a low prevalence of cardiovascular risk factors and cardiovascular disease. These results suggest that the low cardiovascular risk profile and morbidity experienced by these patients may contribute to their prolonged survival on dialysis.


Subject(s)
Cardiovascular Diseases/complications , Kidney Failure, Chronic/therapy , Survivors , Adult , Female , Humans , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/mortality , Male , Middle Aged , Odds Ratio , Risk Factors , Time Factors
17.
J Am Soc Nephrol ; 7(3): 367-86, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8704102

ABSTRACT

Plasma exchange has been used extensively for over 2 1/2 decades to treat a variety of renal diseases. In this article, the scientific rationale for therapeutic plasma exchange in primary and secondary glomerulonephritis, thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, myeloma cast nephropathy, and allograft rejection are reviewed. The clinical studies that evaluate its efficacy are summarized, with special emphasis on the results of randomized controlled trials, when available. Consensus plasma exchange regimens are presented for diseases in which there is evidence to support its use.


Subject(s)
Kidney Diseases/therapy , Plasma Exchange/methods , Animals , Humans , Plasma Exchange/adverse effects , Plasmapheresis
18.
Clin Nephrol ; 44(5): 284-9, 1995 Nov.
Article in English | MEDLINE | ID: mdl-8605707

ABSTRACT

When loss of graft function occurs more than six months after transplantation, allograft nephrectomy is not routinely performed at the time of graft failure. It is usually performed only on those patients who subsequently develop specific complications. However, little is known about the characteristics that make patients more likely to require allograft nephrectomy. The purpose of our study was to identify risk factors for the subsequent need for allograft nephrectomy in patients with graft failure occurring more than 6 months after transplantation. Forty-one patients were studied. Inclusion criteria were: loss of graft function > or = 6 months after transplantation, resumption of dialysis and initiation of weaning from immunosuppression. Thirty patients were treated with cyclosporine + prednisone +/- azathioprine and 11 with azathioprine + prednisone. Mean follow-up time was 17.8 months, ranging from 6 months to 6.1 years. Recipient age, sex and race, original renal disease, donor, donor source (cadaveric vs living related), HLA compatibility, levels of panel reactive antibodies, occurrence of initial delayed graft function, causes of graft failure and tapering of immunosuppression were similar in patients with and without allograft nephrectomy. Using univariate analysis, allograft nephrectomy was found to be significantly more frequent in patients with a history of 2 or more episodes of acute rejection than in patients with no rejection episode: 83% vs 30% (p = 0.03). In addition, allograft nephrectomy was found to be significantly more frequent if the immunosuppressive regimen included cyclosporine (62% vs 27.3%; p = 0.04). Using multivariate analysis however, the number of previous episodes of rejection was found to be the only significant predictor for allograft nephrectomy. None of the other variables considered in the multivariate analysis, including the type of immunosuppressive therapy, was identified as a significant predictor for the need to perform allograft nephrectomy. In summary, the need for late allograft nephrectomy was correlated with the number of previous episodes of acute rejection. Patients with a history of numerous rejection episodes should thus be considered more likely to require allograft nephrectomy once immunosuppression is withdrawn. Possible interventions to reduce or prevent the need for nephrectomy include more gradual tapering of immunosuppression at the time of graft failure or indefinite low-dose immunosuppressive therapy.


Subject(s)
Graft Rejection/surgery , Kidney Transplantation/immunology , Nephrectomy , Adult , Female , Follow-Up Studies , Graft Rejection/prevention & control , Humans , Immunosuppressive Agents/therapeutic use , Male , Retrospective Studies , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...